编辑丨于靖
2022年第一季度是三年来新股发行最慢的一个季度,迫使初创的制药企业在更艰难的融资环境中另寻出路。
想要上市的生物科技公司正面临着一个与一年前完全不同的世界。
行业股价暴跌,过去两年创下纪录的IPO步伐也因此放缓。初创的制药企业再也无法获得2021年...查看全文
chuminhua2022-03-28 16:26
3月25日,AN2 Therapeutics 扩大 IPO 规模,募集 6900 万美元用于从辉瑞(Pfizer)的 Anacor Pharmaceuticals 获得的抗生素epetraborole的关键试验。
epetraborole 是一种细菌亮氨酰-tRNA 合成酶的小分子抑制剂,Anacor 和葛兰素史克在十多年前进行了临床试验。葛兰素史克在 2 期试验中发现一...查看全文
$AN2 Therapeutics(ANTX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-22-071465 Size: 14 KB 网页链接
$AN2 Therapeutics(ANTX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-22-018296 Size: 5 KB 网页链接
$AN2 Therapeutics(ANTX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-22-018293 Size: 5 KB 网页链接
$AN2 Therapeutics(ANTX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-22-018286 Size: 5 KB 网页链接
$AN2 Therapeutics(ANTX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-22-018287 Size: 5 KB 网页链接
$AN2 Therapeutics(ANTX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-22-018289 Size: 5 KB 网页链接
$AN2 Therapeutics(ANTX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-22-018290 Size: 5 KB 网页链接
$AN2 Therapeutics(ANTX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-22-018292 Size: 5 KB 网页链接
$AN2 Therapeutics(ANTX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-22-018276 Size: 5 KB 网页链接
$AN2 Therapeutics(ANTX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-22-018278 Size: 5 KB 网页链接